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Hepatocellular carcinoma (HCC) is one of the deadliest cancers due to its complexities, reoc-
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currence after surgical resection, metastasis and heterogeneity. In addition to sorafenib and
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lenvatinib for the treatment of HCC approved by FDA, various strategies including transar-
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terial chemoembolization, radiotherapy, locoregional therapy and chemotherapy have been
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investigated in clinics. Recently, cancer nanotechnology has got great attention for the treatment of various cancers including HCC. Both passive and active targetings are progressing
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at a steady rate. Herein, we describe the lessons learned from pathogenesis of HCC and the

Hepatocellular carcinoma

understanding of targeted and non-targeted nanoparticles used for the delivery of small

Cancer nanotechnology

molecules, monoclonal antibodies, miRNAs and peptides. Exploring current efficacy is to en-

Cell response

hance tumor cell response of chemotherapy. It highlights the opportunities and challenges

Chemotherapy

faced by nanotechnologies in contemporary hepatocellular carcinoma therapy, where personalized medicine is increasingly becoming the mainstay. Overall objective of this review is
to enhance our understanding in the design and development of nanotechnology for treatment of HCC.
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Introduction

Hepatocellular carcinoma (HCC) is the sixth most malignant
human cancer and rank third in cancer-related deaths globally
among cancer patients. The incidence also is geographically
related, as is the mortality, with Eastern and South-Eastern
Asia and Western Africa having a high incidence [1–3]. HCC
usually occurs in the established background of liver cirrhosisdue to the endopathic cause and exopathic cause often varies
considerably across areas and populations. Normally, HCC can
be treated curatively with surgical resection or liver transplantation if diagnosed early [4]. However, since the majority of
HCC patients are diagnosed at an advanced stage, their median survival times are generally less than 1 year, leading to
a poor prognosis [5]. One reason is surveillance programs are
not widely implemented, despite being recommended in national guidelines [6]. On the other hand, prevention of alcohol
intake, vaccination against hepatitis B virus (HBV) infection,
intake of vitamin D and calcium can prevent HCC in many
cases [7]. However, they could not be used to obliterate the disease. Furthermore, many investigations have shown that the
occurrence of this multi-stage carcinogenesis evolves through
dysregulation of multiple signaling pathways, genetic alterations with the initiation of inflammatory responses leading to the formation of a heterogeneous solid tumorous mass
[8]. Implementation of such programs has only resulted in an
early diagnosis in some rich places [9].
To date, there are six treatments can extend life expectancy
of patients with HCC: surgical resection, liver transplantation,
radiofrequency ablation, transcatheter arterial chemoembolization (TACE), sorafenib and lenvatinib [10,11]. One
third of patients are eligible for potentially curative therapies,
which include resection, transplantation or local ablation, and
such curative treatment can extend median survival times
beyond 60 months [12]. Unfortunately, most patients are still
diagnosed at advanced disease stages. In this setting, only
treatment with sorafenib (the first FDA approved molecularly
targeted drug for HCC treatment) is able to improve overall
survival in the last few decades [13]. In 2018, lenvatinibcapsules (Lenvima, Eisai Inc.) was approved by FDA for the
first-line treatment of un-resectable hepatocellular carcinoma
and showed better subordinate clinical endpoints when compared with sorafenib [14].Although the anti-cancer potency of
sorafenib, lenvatinib and some other drugs have been proven,
poor aqueous solubility, pharmacokinetics and undesirable
side effects make the approach difficult to apply widely in
HCC patients [15]. The major side effects of these drugs treatment are elevated blood pressure, diarrhea, fatigue, hand-foot
syndrome, skin rash/desquamation, and nausea [16]. The
poor aqueous solubility and side effects might be overcome
by the use of nanotechnologies that can control and target
the release of effective drugs to the specific tumor site [17].
With increasing numbers of nanotherapeutics and nanodiagnostics being commercialized or having reached clinical
stage in recent years [18]. Plenty of drug delivery vehicles have
been developed from different biomaterials, such as synthetic
polymers [19–24], natural polymers [25–28], microsphere
liposomes [29–31], peptide [32–36], small molecules [37–41],
and protein [42–46] et al. Specific cancer nanotechnologies

have been proven to be efficacious with respect to better
targeting and minimizing the non-specific cytotoxic effect to
the surrounding organs [47–51]. Targeting the receptors by
drug delivery nanoparticles could significantly alleviate the
adversities of chemotherapy [52,53]. Significant achievements
also have been witnessed in the field of HCC drug delivery systems [52,54,55]. Understanding the biological processes of the
distribution or/and retention of nanoparticles inside the HCC
microenvironment is therefore essential to the development
of personalized nanomedicine approaches. Herein, we examine the fundamentals behind targeting of nanoparticles to
HCC and cancer cells. We will discuss the causes and recent
treatment modalities of HCC, with an emphasis on cancer nanotechnology for enhancing HCC cell response to
chemotherapy. With the perspective of developing new therapeutic nanotechnologies, we will also examine how the
physicochemical parameters of the nanoparticles affect their
localization, retention, cell binding, internalization, efficacy
and toxicity.

2.
Current treatment strategies for
hepatocellular carcinoma
HCC has been well investigated as a complex multi-step
process arising from combination of genetic and epigenetic
alterations, somatic mutations, genomic instability and
environmental factors [56]. There are multiple factors responsible for the initiation and progression of HCC including
virus-induced [56,57], alcohol-induced, fungi-induced obesity
and type II diabetes [58,59]. Common treatment strategies are
composed of surgical (resection and liver transplantation) and
nonsurgical approaches (transarterial chemoembolization,
transartetial radiation, percutaneous local ablation, microwave ablation and systemic therapy). In nonsurgical drug
therapy, not only small molecule drugs such as sorafenib and
lenvatinib, but also gene therapy, immunotherapy and combination therapies have been used for HCC therapy [60–62].
Among them, systemic therapies which using small molecule
drugs to target various signaling pathways following surgical
resection and liver transplantation have been applied particularly where locoregional therapy has been confirmed invalid
[59,63]. However, small molecular chemotherapy in HCC
also suffers from the drawbacks of dose-limiting toxicities,
development of multidrug resistance (MDR) and unfavorable
side-effects like other cancers [64–67]. Although various
multikinase inhibitors have been used for systemic treatment
of HCC, only few drugs such as sorafenib (orally active multikinase inhibitor) and lenvatinib (oral multi-targeted tyrosine
kinase inhibitor) have been approved as deserves special
mention drug for treatment of advanced HCC. Many investigations have indicated that it could prolong overall survival in
patients and delay the time to progression of advanced HCC
by using sorafenib or lenvatinib. However, fatigue, diarrhea,
hypertension, skin toxicity, weight loss, hypophosphatemia
are almost the frequent symptoms amongst patients with
these two drugs’ treatment. Further, various first line and second line therapies are currently under evaluation for the HCC
treatment, however, potential randomized trial with another
drugs such as sunitinib, tivantinib, brivanib and linifanib have
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been disappointing due to the adverse effects and not superior to sorafenib. Only lenvatinib capsules (Lenvima, Eisai Inc.)
have been demonstrated that were noninferior than sorafenib
for overall survival. In view of the failures of clinical trials for
most of the chemotherapeutics drugs, elaborate and extensive information of the underlying molecular mechanisms
undergoing in each patient’s tumor progression is critically
necessary. Other small molecule targeted therapies such as
regorafenib, doxorubicin, gefitinib, vatalanib, cediranib, bortezomib (proteasome inhibitor), rapamycin, sirolimus, and gemcitabine as single agent or in combination with mAb have been
evaluated in clinical trials targeting pathways which are activated in HCC. Recently, combination therapies also have been
widely studies and shown many positive results [65,68,69].
In addition, two other types of molecular-based therapies
are currently under development for the treatment of HCC:
epigenetic modifying therapies [70] and microRNAs (miRNAs)
[71]. Epigenetic modifications in certain genes have been
proposed to drive progression of HCC. Therapies targeting
epigenetic modifiers, such as DNA methyltransferases and
histone deacetylases, are attractive approaches [72,73]. A multicenter phase I/II trial of the histone deacetylase inhibitor
belinostat for treatment of patients with HCC is currently
being developed [74]. Some other researches also showed that
those with high immunoreactivity to the UV excision repair
protein RAD23 homologue B (HR23B) to HDAC inhibitors had a
higher rate of disease stabilization [75]. Bitzer et al. have studied the resminostat plus sorafenib as the second line therapy
and showed potential activity in patients with HCC [76].
MiRNAs-based strategies that block the interaction of HDAC
with its substrates have also been studies [77–79]. The results
showed that many kinds of miRNAs are important regulators
of gene expression and associated with the development of
HCC [80,81].
Otherwise, their value in clinical management has been
investigated. Functional screens of miRNAs have identified
key regulators of glypican-3, a surface proteoglycan that acts
as a co-receptor, controls cell apoptosis, proliferation and is
a potential target for treatment of HCC [78]. In a word, evidence suggests that miRNA-based therapies are worthwhile
approaches to cancer treatment. Shuai and his co-workers
have investigated the folate-targeted theranosticsiRNA (FaPEG-gPEI-SPION/psiRNA-TBLR1) nanoparticles for enhanced
HCC chemotherapy and obtained the positive results (Fig. 4).
Recently, cancer immunotherapy rises rapidly and also
plays a critical role in HCC treatment due to the liver as the
mainimmune organ of the lymphatic system [79,82,83]. Three
kinds of hepatic cells named liver sinusoidal endothelial cells,
Kupffer cells and dendritic cells (DCs) are main roles for the
immune response in the HCC microenvironment [84]. However, only few immunotherapy trials for HCC have been studied so far with contrasting results, suggesting that significant
improvements are needed. It is beyond a doubt that such an
inherent immune tumor environment needs to be taken into
account and counterbalanced when immunotherapeutic approaches are designed and implemented in HCC. Therefore,
combination therapy of monoclonal antibodies or chemotherapies along with transarterial chemoembolization is a promising approach in increasing the overall survival of HCC patients
whose chances of relapse after surgery are evident [85,86]. Pre-
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vious studies have shown promising safety, efficacy and tumor
targeting of the 131I-labeled metuximab and transcatheter arterial chemoembolization combination for unresectable HCC
[87,88]. Combination of low dose cyclophosphamide treatment with a vaccine (e.g. telomerase vaccine) in HCC has been
evaluated in a single clinical trial [89,90]. Unfortunately, the
combination did not show antitumor efficacy in respect to tumor response and time to progression. Nearly 5 years, PD-1
and its ligand PD-L1 have been widely used as an immune regulating checkpoint with a well-established role in the development of HCC progression. A single clinical trial in HCC patients has been reported combining anti-PD-1 Ab and a GPC3
peptide vaccine. Results showed improved antitumor effects
of a peptide vaccine correlating with the increased levels of
vaccine-specific CTLs and reduced tumor-infiltrating T cells
[88]. Nivolumab is an immunotherapy that inhibits PD-1.It has
been used as a second line systemic treatment in HCC patients
who have been treated with or intolerant to sorafenib and has
been granted approval by FDA in 2017. To increase responses
to immunotherapy, combination of PD-1 or PDL1 and tyrosine kinase inhibitors are currently investigated significant
improved clinical outcomes. Xu et al. generated and used SHR1210 (anti-PD-1 antibody) and apatinib (VEGFR2 inhibitor) to
study combination therapy treatment with advanced HCC. It
was found that combination therapy demonstrated manageable toxicity and encouraging clinical activityin patients [91].
Markus Joerger et al. also provided data from this clinical case
to support the potential of combination treatment of the oral
multi-kinase inhibitor regorafenib with PD-1 or PDL1 targeted
monoclonal antibodies to advanced HCC therapy [92]. These
discoveries can be used to promote the development of HCC
immunotherapy. After the completion of genome-wide association studies (GWAS) and pharmacogenomics, personalized
medicine has gradually become possible in HCC. Personalized
medicine has been the mainstay for the treatment of HCC. Personal genetic analysis can hold the promise of identifying patients and family members, who would benefit from personalized medicine, modifying risk factors and so on [93,94].

3.
Application of nanomedicine for
hepatocellular carcinoma therapy
Although the efficiency of these few chemotherapeutics
molecules in the management of HCC, the drugs are not usually delivered at high concentrations into the malignant tissues. Thereby, hydrophobicity, toxicity and bioavailability of
these small molecular drugs caused dose-limiting side effects are still the deliver challenge. Nanotechnology is a powerful tool for the delivery and targeting of therapeutics in
HCC [95–97]. Since HCC cells undergo genetic and phenotypic changes compared to other hepatic cells, targeting of
HCC cells is an obvious avenue for treatment of HCC (Fig. 1).
Various targeting and delivery strategies have been explored
for nanoparticles (NPs) [98–100], micelles [101,102], liposomes
[103] both passively and receptor-mediated active targeting in
HCC. Normally, nanotechnologies could overcome the unfavorable side-effects of systemic administration of chemotherapeutics by improving the pharmacokinetics, biodistribution,
accumulating cytotoxic agents in tumor site and elevating
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Fig. 1 – This diagram summarizes known therapies for treatment of HCC receptors, and the cellular locations of drug-target
interactions.

the effectiveness of treatment through drug delivery nanosystems [104–107]. Nanometer size range of nanosystems could
help drugs reach the tumor cells through the leaky vasculature and enhance site-specific enhanced delivery [108]. However, degradability, stability, circulation,metabolismas well as
the balance between side effects and curative effect still
have to be carefully considered for the design of efficient deliver nanosystems. Otherwise, HCC patients almost developed
based on prolonged inflammatory processes, which emerged
as a result of genetic and epigenetic alterations. Tumor suppressor genes, in particular p53 and retinoblastoma, are the
frequently altered in HCC. Further, as a kind of highly vascular tissues, HCC progression is almost accompanied by
abnormal angiogenesis at different stage and etiology.
Thereby, angiogenesis related molecules such as VEGFR, RAF
and EGFR are extremely useful targets in the development of
selective therapeutics. Hence, the specific surface molecules
of liver cells including ASGPR and endocytic cell surface receptors are highly expressed by HCC cells that are distinguished
from other tissues. These specific related genotypic and phenotypic alterations have been utilized for HCC targeting diagnosis and therapy. Herein, some of the recent designs and
findings in the field of nano-based medicines for passive and
receptor-specific active targeting for the treatment of hepatocellular carcinogenesis would be discussed.

are taken up by the liver after only a few minutes due to the
opsonization process. To date, various stimuli including pH,
enzymatic, redox, light and heat have been used for passive
targeting of nanoparticles carrying drugs in HCC [112,113]. Recently, nanoassemblies based on supramolecular complexes
of nonionic amphiphiliccyclodextrin and sorafenib as effective weapons to kill HCC cells have been developed (Fig. 2)
[114]. Sorafenib robustly interacts with nonionic amphiphiliccyclodextrin, forming supramolecular complexes that behave as building passive targeting nanoassemblies. These
nanoassemblies are highly stable in aqueous medium, retaining sorafenib up to 2 weeks. Interestingly, these passive targeting systems show very low hemolytic activity and a high efficiency to inhibit the growth of three different HCC cell lines,
similarly to free sorafenib, which indicated the preferential in
vivo accumulation of nanoassemblies could result in a superior therapeutic efficacy than the free drug.Antisense-miRNA21 and gemcitabine (GEM) co-encapsulated PEGylated-PLGA
NPs have been developed to overcome drug resistance and improve their therapeutic efficacy in vitro. For lenvatinib, Yuan
et al. have developed aliposome-encapsulated contrast agent
comprising lenvatinib-bound nanoparticles for screening of
early–phase non–small cell lung cancer. However, nanotechnology has not been used for enhancing the HCC therapy of
lenvatinib.

3.1.
Passive targeting nanotechnology for hepatocellular
carcinoma therapy

3.2.
Active targeting nanotechnology for hepatocellular
carcinoma therapy

In case of passive targeting, nanomedicines can reach tumor
via the leaky vasculature of the tumors by the enhanced permeability and retention (EPR) effect [109–111]. Nanoparticles
can be delivered to specific sites by passive targeting. It also
has been reported that nanoparticles injected intravenously

Although nanosystems have gained tremendous success for
delivering chemotherapeutic agents, their rapid clearance by
the reticuloendothelial system (RES) after systemic administration restricts them from their delivery to hepatocytes which
are the main site for HCC origination [115,116]. As a result,
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Fig. 2 – Sketched view of nanoassemblies formation in aqueous solution (Reproduced with permission from [67]. Copyright
2017 Shenyang Pharmaceutical University).

the nanotechnological approaches of site specific and/or targeted drug delivery amenable to distinct hepatic cells and
their receptors are being studied extensively by researchers
[117–119]. Further, active targeting was almost accompanied
with passive targeting when nanosystems were designed
[120–122].
Asialoglycoprotein receptor (ASGPR) has been identified
as a commonly found lectin receptor which is profoundly
expressed in mammalian liver cells [123,124]. Using natural
ligands such as asialofeutin as well as synthetic ligands
could achieve specific liver ASGPR targeting [58]. For example,
nanoparticles and liposomes incorporating various lactosylated strategies have been evaluated for targeting efficacy to
hepatic tumor cells. Polyethylene sebacate (PES)-Gantrez®
AN 119 Dox NPs have been developed with ASGPR ligands
by Sandhya et al. and showed the high efficacy coupled
with greater safety as a promising nanocarrier for improved
therapy of HCC [125]. Meng and colleagues successfully
demonstrated the galactose-installed photo-crosslinked pHsensitive degradable micelles (Gal-CLMs) for active targeting
chemotherapy have a great potential for hepatocellular carcinoma chemotherapy (Fig. 3) [126]. In another study, cholesterol
arabinogalactan anchored liposomes (CHOL-Al-AG) carrying
DOX targeting ASGPR receptors on mammalian hepatocytes
in HCC were studied where improved delivery of DOX was
reported in terms of stability, loading efficiency, tumor regression both in vitro and in vivo compared to unmodified
liposomes [127].
Integrins are transmembrane receptors which are responsible for cell–cell and cell-extracellular matrix interactions
[128]. Hepatic stellate cells almost express integrins when
it suffers fibrotic liver [129]. For instance, the peptide sequence RGD acts as a targeting ligand for collagen VI and
RGD-coupled liposomes has been extensively applied for
targeting integrin receptors in HCC [130]. To deliver the poor
water soluble drug paclitaxel (PTX) effectively in HCC, Chen et
al. have developed a kind of integrin-αvβ3 receptor targeted
liposomal PTX [131]. RGD-motif was successfully conjugated

to DSPE-PEG to prepare RGD-modified liposomes (RGD-LP).
Both in vitro and in vivo studies demonstrated RGD-LP-PTX
had enhanced anti-proliferative and tumor growth inhibitory
effects activity against HepG2 cells and HepG2-bearing mice
tumor respectively than RGD-LP or free PTX. Moreover, combination of DOX and sorafenib in iRGD decorated lipid-polymer
hybrid core-shell structured NPs also indicated enhanced
antitumor efficacy in HCC in vivo models with improved
bioavailability and longer circulation time [132]. Recently,
RGD modified lipid-coated NPs for the co-delivery of the
hydrophobic drugs have been used by Wang et al. to against
hepatocellular carcinoma. The combination of sorafenib and
quercetin formulations was more effective than the single
drug formulations in both NPs and solution groups. This RGD
modified NPs achieved the most significant tumor growth
inhibition effect in vitro and in vivo [133].
Vandetanib is an oral inhibitor of VEGFR, EGFR, RETtyrosine kinase and has been approved for medullary thyroid
cancer [134]. It has been explored for HCC as encapsulated NPs
with targeting moiety with enhanced antitumor efficacy [135].
HCC cells overexpressed transferrin (Tf) receptors which
have become useful targeting avenues for potential treatment [136]. The ideal of sorafenib in albumin nano-shell
was used and DOX was loaded in poly (vinyl alcohol) as
nano-core, the interactions were simulated and then the
nanomedicines were formed by a sequential freeze-thaw/
coacervation method (Fig. 5) [137]. It indicated that rationally designed core-shell nanoparticles can effectively combine clinically relevant single-agent drugs for exerting synergistic activity against liver cancer.
CL4 RNA aptamer specific to EGFR and CD133 targeted aptamers was conjugated to PLGA nanoparticles was studied for
salinomycin delivery to cancer stem cells in HCC treatment
[138].
Like other cancers, folate receptors are significantly overexpressed in HCC and to target these receptors, its natural ligand, folic acid (FA) has been explored for nanoparticle
drug delivery to the cancer cells [3,139]. Xu et al. studied the
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Fig. 3 – Illustration of pH-sensitive degradable micelles as an integrative nanovehicle for active targeting hepatocellular
carcinoma chemotherapy (Reproduced with permission from [114]. Copyright 2015 American Chemical Society).

antitumor potency of the folate receptor-targeted liposomes
(FA-PEG-DSPE) co-delivery of antitumor agent docetaxel and
iSur-pDNA in vitro and in vivo [140].
VEGF receptors are found to be overexpressed in HCC due
to the receptor activation via multiple signaling pathways
[140,141]. Recently, iRGD-decorated polymeric NPs for the efficient delivery of vandetanib to HCC have been investigated.
Wang et al. studied the biodegradable PEG-PLA to nanoprecipitate this potent agent to form water-soluble NPs that are suitable for intravenous administration [142]. Active targeting by
aptamer-mediated delivery showed significant anti-tumor efficacy when tested both in vitro and in vivo. The results also
demonstrate that reformulating targeted therapeutic agents
in NPs permits their systemic administration and thus significantly improves the potency of currently available, orally delivered agents.
Glycyrrhetinic acid (GA) receptor is overexpressed on the
hepatocyte surface and has been extensively studied for drug
targeting [143]. Qi et al. reviewed the roles of this receptor
and GA-mediated drug delivery in HCC [144]. GA-modified
nanoparticles formulations of DOX exhibited a much higher
level of tumor accumulation than nontargeted NPs at 1 h after injection in hepatoma-bearing Balb/c mice. Zhang and colleagues studied poly (L-Histidine) (PHIS) mediated polymeric
system (GA-PEG-PHIS-PLGA) with GA for targeted delivery of
the anti-cancer agent and rographolide [145].

Passive and active targeting nanotechnologies have shown
some potential for hepatocellular carcinoma therapies. However, tumor recurrence needs deeper or more thorough therapies, such as combination targeting, long circulation and so
on. There are still many challenges for nanotechnology to fabricate more ideal delivery systems.

4.
Influence of the architecture of
nanomedicine for hepatocellular carcinoma
therapy
The conjugation of ligands on the liver cells surface of
nanosystems changes not only the properties of the targeting
molecules but also the nanocarriers. From a chemical point
of view, while ligands bind to the surface of NPs, it would
lose the rotational and translational freedom bestowed to free
molecules, otherwise, the new targeted entity achieves improved avidity due to the increased valency. Similarly, the size,
shape, surface properties (charge, density and hydrophobicity), and composition of NPs can also be the influence factors [146,147]. Fig. 6 shows the various properties of NPs which
could change the delivery behavior of drugs from NPs to HCC
cells. As we know, targeted NPs have shown benefits that go
beyond the simple delivery of anti HCC drugs in many cases.
To fully understand the properties of targeted NPs, it is impor-
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Fig. 4 – Illustration of the folate-targeted theranostic small interfering RNA (siRNA) nanomedicine
Fa-PEG-gPEI-SPION/psiRNA-TBLR1 hepatocellular carcinoma chemotherapy.

tant to determine how the physicochemical properties of the
NPs affect the interactions with their targets. Herein, we will
discuss the main factors such as the ligand density, size and
shape, surface and ligand charge and surface hydrophobicity
of NPs to influence the behaviors of them.

4.1.

The ligand density

For all delivery, the density of the targeting molecules on the
surface of NPs impacts their affinity for the substrate due
to increased cooperative effects. According to the thermodynamics, the more binding of a ligand to its substrate would
promote the subsequent binding of its neighbors [148]. Biologically, increasing the ligand density would aggrandize the
interactions of the NPs with the cell membrane so that force
the local concentration of receptors and lead to internalization of cell membranes. These synergistic effects impede the
detachment of the NPs from the cell surface and result in increased avidity [149].
The increasing ligand density usually results in improved
cellular uptake in vitro [150]. However, targeting ligand density

is critical to maximizing the efficiency of targeting NPs to
cancer cells, and further increasing in ligand density will have
deleterious effects on cell binding beyond the cooperative effect of the ligand get saturate. The reason of this effect might
due to the improper orientation of the ligand, steric hindrance
of neighboring molecules or competitive behaviors for the
binding of the receptor [151]. Similar negatively cooperative
effect has been observed in ligand-clustered NPs where the
ligands are arranged in patchy clusters by Hammond group
[152]. Valencia et al. have investigated and showed that
the use of high densities of hydrophobic ligands can increase the macrophage uptake of the NPs without providing
significant advantages in terms of receptor-mediated internalization [153].
Similar effects have been observed in vivo where higher
densities do not always result in improved efficacy. Many studies have shown that the alteration of the NPs surface to incorporate the ligands can modify the blood circulation and
biodistribution profiles of the NPs. Gu et al. have developed
the aptamer-targeted polymeric NPs and shown that increasing the ligand density above 5% would cause the increasing
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Fig. 5 – In silico docking simulation of core–shell nanomedicine (Reproduced with permission from [85]. Copyright 2016 Lin
et al.).

Fig. 6 – The physicochemical properties of the ligand and the NP affect their blood circulation profiles, their biodistribution
and their ability to be internalized by cancer cells.

clearance of the NPs by the liver and the spleen and impeded
the distribution to the tumor [154].
Finally, many studies indicated that tumor selective antibodies could suffer from a binding-site barrier preventing
their in-depth diffusion in the tumor [155,156]. This phenomenon is observed when high affinity molecules rapidly
bind perivascular cells surrounding the cancer cells upon their

extravasation to the tumor. The binding-site barrier also limits
the in-depth diffusion of small molecular weight drugs with
high affinity for HCC cells. This effect has been recently targeted to the receptors NPs which showed not enough HCC
cells penetration compared to their non-targeted counterpart.
Interestingly in that case, the binding-site barrier effect was
not observed with larger NPs, presumably because of differ-
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ences in the rates of HCC cells penetration and/or cell internalization. Therefore, it seems probable that adequately tuning the ligand density on the NP surface could mitigate the
binding-site barrier effect and translate into adequate retention time and maximal cellular uptake throughout the HCC
[157].

4.2.

Size and shape

The size and shape of the nanomaterial must be taken into
consideration early in the design of targeted NPs. For HCC,
smaller sizes and spherical shape represent higher curvatures might promote hepatic targeting but can be problematic for post synthesis ligand functionalization. In addition,
the tethering of high molecular weight ligands on the surface
of NPs would increase their hydrodynamic radius [158]. This
increase in size must always be considered in light of the possible size restrictions involved in tumor accumulation. Besides
the above mentioned effects, size can also affect cellular uptake. Although, the avidity of the particle increased with size
range from 2 to 70 nm, the maximum uptake is a compromise
between high avidity and optimal cell membrane wrapping
around the NPs. Additionally, it is not clear how these conclusions can be expanded to other systems, as the interactions
between NPs and cell highly-depend on the physicochemical
properties of each material. In vivo, Lee et al. have reported that
the size of actively targeted NPs could affect the intracellular
deposition, not only in liver. In this case, although the intratumoral accumulation of smaller NPs was decreased due to
shorter blood circulation times, the cytoplasmic and nuclear
distribution of the 25-nm NPs was superior to that of the 60nm colloids [158,159]. Moreover, the shape of NPs might influence the cell uptake kinetics and internalization pathways
through modulating the nanomaterial interact with the cell
surface [160].

4.3.

Surface and ligand charge

Chemically, the charge of unfunctionalized NPs and that of
the ligand can affect the conjugation yield and the spatial display of the ligand on the surface. Repulsive or attractive forces
between the surface of the NPs and the ligand can interfere
with the conjugation or affect the final ligand structure and
conformation. A chemical spacer with reasonable length,
such as PEG, can be helpful to reduce the effect, but might
simultaneously complicate synthesis and increase the final
particle size [161,162]. Previous study also showed that the
final surface charge will affect the efficacy of the targeted NPs
[163]. For HCC, due to the interaction between cationic NPs
and negatively charged cell membranes, positively-charged
NPs show increased cellular binding and uptake, in a first pass
effect and non-specific manner [164]. Because most ligands
are charged molecules, the NPs surface charge is determined
by the combinations of ligand densities, materials, NP formulation strategies and so on. Although recent work was
carried out to address how charge density affects interactions
of actively targeted NPs with HCC cells and NPs charge can
affect cellular uptake, it remains unclear what parameters
offer the best hepatic targeting in vivo.

4.4.
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Surface hydrophobicity

Except surface charge and above factors, hydrophobicity can
also affect the architecture of the ligand display. Further, this
property can have serious effects since most polymeric NPs
have hydrophobic cores. Previous studies have shown that
during the self-assembly of polymeric hydrophobic particles,
hydrophobic ligand such as folic acid could remain trapped
in the particle core without being properly displayed on the
surface. In some cases, the final surface hydrophobicity of
NPs can also affect nonspecific interactions with HCC cells.
Actively targeted NPs without steric stabilization seem to
lose their substrate-binding capacity when proteins adsorb on
their surface. Surface functionalization can delay adsorption
of plasma proteins and has been demonstrated in vitro and in
vivo where the efficacy is dependent on both circulation times
and ligand–substrate interactions.
Overall, although the aforementioned factors hold true for
the majority of therapeutic NPs, no general strategies have
been found suitable to address the limitation of the nanosystems. For HCC therapy, assessing the efficacy of a treatment still requires time and resources, and providing matching targeted delivery nano-systems remain therefore unlikely.
However, most studies have demonstrated the targeting ligand might be key factor to decide the in vivo profiles of
nanoparticles. More and more targeted liposomes and polymeric NPs have been made to clinical development stages
indicating that the decisive role of ligands. With the aim to
transport in depth of tumor, multi-ligands or multi-functional
ligands have been used to alternate the negative effects of
mono-high ligand density.

5.

Conclusion and future prospect

Since HCC is a complex multi-step process influenced by
many factors for its initiation and progression, therapeutic interventions are challenging for this disease. With the rising incidence of HCC and high morbidity and mortality rates associated with this cancer, there is an urgent need to develop effective treatment and prevention strategies. We have reviewed
the various targeted receptors and recent treatment modalities of HCC with emphasis on nanotechnology strategies in
the field of HCC. While surgical resection and liver transplantation are the only strategies available for treating advanced
stage patients, nanomedicines and immunotherapy might be
promising approach for successful treatment of HCC in the
future. Not only safety, toxicity, preclinical efficacy studies
are required thoroughly before any clinical application of
these delivery strategies are further explored. As GWAS and
more comprehensive data sets become available, the clinical
advantages of using nanomedicine for HCC treatment might
be better understood. Based on the personalized medicine,
combined nanomedicines with immunotherapy would be a
fine choice for HCC therapy. Immunotherapy strategies have
exhibited encouraging results for various cancer therapies.
However, the dynamic nature of immune responses at the
HCC sites and some other challenging such as complication of
multi-immune and individual difference would lead to combination nanotechnology and immunotherapy an opportunity
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and challenge coexist in clinic. With the development of immunotherapy, all together these will forecast a bright future
of nanomedicine for hepatocellular carcinoma therapy when
it could control and regulate the immune response from exogenous immune stimulation.
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